参考文献/References:
[1] Wolk MJ,Bailey SR,Doherty JU,et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease:a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force,American Heart Association,American Society of Echocardiography,American Society of Nuclear Cardiology,Heart Failure Society of America,Heart Rhythm Society,Society for Cardiovascular Angiography and Interventions,Society of Cardiovascular Computed Tomography,Society for Cardiovascular Magnetic Resonance,and Society of Thoracic Surgeons[J]. J Am Coll Cardiol,2014,63(4):380-406.
[2] Meijboom WB,van Mieghem CAG,van Pelt N,et al. Comprehensive assessment of coronary artery stenoses:computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina[J]. J Am Coll Cardiol,2008,52(8):636-643.
[3] Shaw LJ,Berman DS,Maron DJ,et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden:results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation(COURAGE) trial nuclear substudy[J]. Circulation,2008,117(10):1283-1291.
[4] Pijls NHJ,Fearon WF,Tonino PAL,et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease:2-year follow-up of the FAME(Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study[J]. J Am Coll Cardiol,2010,56(3):177-184.
[5] de Bruyne B,Pijls NH,Kalesan B,et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J]. N Engl J Med,2012,367(11):991-1001.
[6] Lawton JS,Tamis-Holland JE,Bangalore S,et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization:executive aummary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(3):e4-e17.
[7] Murthy VL,Bateman TM,Beanlands RS,et al. Clinical quantification of myocardial blood flow using PET:joint position paper of the SNMMI Cardiovascular Council and the ASNC[J]. J Nucl Med,2018,59(2):273-293.
[8] Dekemp RA,Declerck J,Klein R,et al. Multisoftware reproducibility study of stress and rest myocardial blood flow assessed with 3D dynamic PET/CT and a 1-tissue-compartment model of 82Rb kinetics[J]. J Nucl Med,2013,54(4):571-577.
[9] Danad I,Raijmakers PG,Driessen RS,et al. Comparison of coronary CT angiography,SPECT,PET,and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve[J]. JAMA Cardiol,2017,2(10):1100-1107.
[10] Driessen RS,van Diemen PA,Raijmakers PG,et al. Functional stress imaging to predict abnormal coronary fractional flow reserve:the PACIFIC 2 study[J]. Eur Heart J,2022,43(33):3118-3128.
[11] Valenta I,Antoniou A,Marashdeh W,et al. PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients[J]. Eur Heart J Cardiovasc Imaging,2017,18(5):538-548.
[12] Sharir T,Ben-Haim S,Merzon K,et al. High-speed myocardial perfusion imaging initial clinical comparison with conventional dual detector anger camera imaging[J]. JACC Cardiovasc Imaging,2008,1(2):156-163.
[13] Wells RG,Marvin B,Poirier M,et al. Optimization of SPECT measurement of myocardial blood flow with corrections for attenuation,motion,and blood binding compared with PET[J]. J Nucl Med,2017,58(12):2013-2019.
[14] Agostini D,Roule V,Nganoa C,et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera:head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study[J]. Eur J Nucl Med Mol Imaging,2018,45(7):1079-1090.
[15] de Souza ACDAH,Harms HJ,Martell L,et al. Accuracy and reproducibility of myocardial blood flow quantification by single photon emission computed tomography imaging in patients with known or suspected coronary artery disease[J]. Circ Cardiovasc Imaging,2022,15(6):e013987.
[16] Wang L,Wu D,Yang Y,et al. Avoiding full corrections in dynamic SPECT images impacts the performance of SPECT myocardial blood flow quantitation[J]. J Nucl Cardiol,2017,24(4):1332-1346.
[17] Ma R,Wang L,Wu D,et al. Myocardial blood flow quantitation in patients with congestive heart failure:head-to-head comparison between rapid-rotating gantry SPECT and CZT SPECT[J]. J Nucl Cardiol,2020,27(6):2287-2302.
[18] Chen LC,Hung HF,Jong BH,et al. A method to measure the extent of myocardial ischemia and steal with SPECT myocardial blood flow quantitation[J]. Ann Nucl Med,2020,34(9):682-690.
[19] Beller GA. Underestimation of coronary artery disease with SPECT perfusion imaging[J]. J Nucl Cardiol,2008,15(2):151-153.
[20] Ziadi MC,Dekemp RA,Williams K,et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease?[J]. J Nucl Cardiol,2012,19(4):670-680.
[21] Fiechter M,Ghadri JR,Gebhard C,et al. Diagnostic value of 13N-ammonia myocardial perfusion PET:added value of myocardial flow reserve[J]. J Nucl Med,2012,53(8):1230-1234.
[22] Wang L,Zheng Y,Zhang J,et al. Diagnostic value of quantitative myocardial blood flow assessment by NaI(Tl) SPECT in detecting significant stenosis:a prospective,multi-center study[J]. J Nucl Cardiol,2022 Aug 15. DOI: 10.1007/s12350-022-03085-3.?Online ahead of print.
[23] Hsu B,Chen FC,Wu TC,et al. Quantitation of myocardial blood flow and myocardial flow reserve with 99mTc-sestamibi dynamic SPECT/CT to enhance detection of coronary artery disease[J]. Eur J Nucl Med Mol Imaging,2014,41(12):2294-2306.
[24] Herzog BA,Husmann L,Valenta I,et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve[J]. J Am Coll Cardiol,2009,54(2):150-156.
[25] di Carli MF. PET perfusion and flow assessment:tomorrows’ technology today[J]. Semin Nucl Med,2020,50(3):227-237.
[26] Murthy VL,Naya M,Foster CR,et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve[J]. Circulation,2011,124(20):2215-2224.
[27] Del Buono MG,Montone RA,Camilli M,et al. Coronary microvascular dysfunction across the spectrum of cardiovasculardiseases:JACCstate-of-the-art review[J]. J Am Coll Cardiol,2021,78(13):1352-1371.
[28] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.
[29] Kunadian V,Chieffo A,Camici PG,et al. An EAPCI expert consensus document on ischaemia with n on-obstructive coronary arteries in collaboration with European Society of Cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders I nternational Study Group[J]. Eur Heart J,2020,41(37):3504-3520.
[30] Castagnoli H,Ferrantini C,Coppini R,et al. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy:a 2016 reappraisal[J]. Eur J Nucl Med Mol Imaging,2016,43(13):2413-2422.
[31] Neglia D,Michelassi C,Trivieri MG,et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction[J]. Circulation,2002,105(2):186-193.
[32] Tio RA,Dabeshlim A,Siebelink HM,et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease[J]. J Nucl Med,2009,50(2):214-219.
[33] Naya M,Tamaki N,Tsutsui H. Coronary flow reserve estimated by positron emission tomography to diagnose significant coronary artery disease and predict cardiac events[J]. Circ J,2015,79(1):15-23.
[34] Pepine CJ,Anderson RD,Sharaf BL,et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart,Lung and Blood Institute WISE(Women’s Ischemia Syndrome Evaluation) study[J]. J Am Coll Cardiol,2010,55(25):2825-2832.
[35] Schindler TH,Dilsizian V. Coronary microvascular dysfunction:clinical considerations and noninvasive diagnosis[J]. JACC Cardiovasc Imaging,2020,13(1 Pt 1):140-155.
[36] Kang G,Ha R,Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device i mplantation[J]. J Heart Lung Transplant,2016,35(1):67-73.
[37] Ramzy D,Rao V,Brahm J,et al. Cardiac allograft vasculopathy:a review [J]. Can J Surg,2005,48(4):319-327.
[38] Chih S,Wiefels CC,Beanlands RSB. PET assessment of cardiac allograft vasculopathy[J]. Semin Nucl Med,2021,51(4):349-356.
[39] Bravo PE,Bergmark BA,Vita T,et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy[J]. Eur Heart J,2018,39(4):316-323.
[40] Chih S,Chong AY,Erthal F,et al. PET assessment of epicardial intimal disease and microvascular dysfunction in cardiac allograft vasculopathy[J]. J Am Coll Cardiol,2018,71(13):1444-1456.
[41] Mc Ardle BA,Davies RA,Chen L,et al. Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant[J]. Circ Cardiovasc Imaging,2014,7(6):930-937.
[42] Konerman MC,Lazarus JJ,Weinberg RL,et al. Reduced myocardial flow reserve by positron emission tomography predicts cardiovascular events after cardiac transplantation[J]. Circ Heart Fail,2018,11(6):e004473.
[43] Miller RJH,Manabe O,Tamarappoo B,et al. Comparative prognostic and diagnostic value of myocardial blood flow and myocardial flow reserve after cardiac transplantation[J]. J Nucl Med,2020,61(2):249-255.
[44] Feher A,Srivastava A,Quail MA,et al. Serial assessment of coronary flow reserve by rubidium-82 positron emission tomography predicts mortality in heart transplant recipients[J]. JACC Cardiovasc Imaging,2020,13(1 Pt 1):109-120.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(1):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(1):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(1):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(1):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
[11]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]